Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Aurora Kise B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kise 12 or Serine/Threonine Protein Kise 5 or Serine/Threonine Protein Kise Aurora B or STK1 or AURKB or EC 2.7.11.1) - Overview
Aurora Kise B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kise 12 or Serine/Threonine Protein Kise 5 or Serine/Threonine Protein Kise Aurora B or STK1 or AURKB or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Aurora Kise B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kise 12 or Serine/Threonine Protein Kise 5 or Serine/Threonine Protein Kise Aurora B or STK1 or AURKB or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Aurora Kise B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kise 12 or Serine/Threonine Protein Kise 5 or Serine/Threonine Protein Kise Aurora B or STK1 or AURKB or EC 2.7.11.1) - Companies Involved in Therapeutics Development
AbbVie Inc
Advenchen Laboratories LLC
Amgen Inc
AstraZeneca Plc
Chipscreen Biosciences Ltd
Cielo Therapeutics Inc
Merck & Co Inc
njing Tianyi Bioscience Co Ltd
njing Transthera Biosciences Co Ltd
Nemucore Medical Innovations Inc
Syctix Pharmaceuticals Inc
Vichem Chemie Research Ltd
Aurora Kise B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kise 12 or Serine/Threonine Protein Kise 5 or Serine/Threonine Protein Kise Aurora B or STK1 or AURKB or EC 2.7.11.1) - Drug Profiles
AL-8326 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APIOEE-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-2811 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-137690 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-2164 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
danusertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBPR-114 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilorasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMI-900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit AURKA and AURKB for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit AURKB for Acute Myeloid Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit AURKA and AURKB for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TT-00420 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TY-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aurora Kise B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kise 12 or Serine/Threonine Protein Kise 5 or Serine/Threonine Protein Kise Aurora B or STK1 or AURKB or EC 2.7.11.1) - Dormant Products
Aurora Kise B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kise 12 or Serine/Threonine Protein Kise 5 or Serine/Threonine Protein Kise Aurora B or STK1 or AURKB or EC 2.7.11.1) - Discontinued Products
Aurora Kise B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kise 12 or Serine/Threonine Protein Kise 5 or Serine/Threonine Protein Kise Aurora B or STK1 or AURKB or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Nov 07, 2019: TransThera Biosciences lead product TT-00420 granted Orphan Drug Desigtion from FDA to treat Cholangiocarcinoma
Sep 28, 2018: TransThera Biosciences Granted IND Approval from FDA to Soon Start Clinical Trials Targeting TNBC
Dec 21, 2017: Sundia Congratulates NHRI for DBPR114 IND Approval in US & Taiwan
May 10, 2016: Data Published in Jourl of Controlled Release Demonstrate Flexibility of ACCURINS to Encapsulate a Broad Range of Physically and Chemically Diverse Payloads with High Encapsulation Efficiency and Tuble Release Kinetics
Feb 10, 2016: AZD2811 ACCURINS Data Published in Science Translatiol Medicine Highlight One of the First Applications of nomedicine to Molecularly Targeted Cancer Therapies
Nov 18, 2015: BIND Therapeutics Announces Initiation of Clinical Studies with Accurin AZD2811 in Solid Tumors
Jun 23, 2015: BIND Therapeutics Announces FDA Authorization of First-in-Human Clinical Trial with AstraZeneca’s Aurora B Kise Inhibitor Accurin AZD2811
Apr 22, 2015: BIND Therapeutics Presents Data Highlighting Ability of Accurin drug candidate AZD2811 to Accumulate in Target Tissue at AACR Annual Meeting 2015
Mar 18, 2015: Data from Abstracts Validating Potential of BIND Therapeutics AZD2811 to be Presented at American Association for Cancer Research Annual Meeting
Mar 05, 2014: BIND Therapeutics to Present Data on Barasertib at the AACR 2014 Annual Meeting
Sep 03, 2012: Chipscreen filed a new IND application on a novel dual-pathway targeted inhibitor Chiauranib to SFDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Advenchen Laboratories LLC, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Chipscreen Biosciences Ltd, H2 2019
Pipeline by Cielo Therapeutics Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Nanjing Tianyi Bioscience Co Ltd, H2 2019
Pipeline by Nanjing Transthera Biosciences Co Ltd, H2 2019
Pipeline by Nemucore Medical Innovations Inc, H2 2019
Pipeline by Synactix Pharmaceuticals Inc, H2 2019
Pipeline by Vichem Chemie Research Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Dormant Products, H2 2019 (Contd..5), H2 2019
Discontinued Products, H2 2019
Discontinued Products, H2 2019 (Contd..1), H2 2019